It has been shown that obinutuzumab can significantly modulate the phagocytic function of neutrophils in CLL by enhancing neutrophils’ expression of CD16b, which restores recognition and clearance of leukemic cells (132). Here, FCGR3B is linked to B-cell chronic lymphocytic leukemia.